DiaSorin completes EUR 250 million buyback. DiaSorin stock gains 1.34 percent

Published on 10/07/2026 at 13:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue reached EUR 602 million, flat year over year at constant rates. DiaSorin stock costs EUR 77.64 on October 7, 2026 after EUR 76.61.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin (IT0003492391) was trading at EUR 77.64 at Lang & Schwarz on October 7, 2026 at 1:10 p.m. CEST, plus 1.34 percent versus the prior close of EUR 76.61. The company completed its EUR 250 million share buyback, according to Repubblica on October 7, 2026.

Buyback reaches EUR 250 million

DiaSorin bought 40,523 shares on October 5, 2026 at an average EUR 75.81, completing the program launched on January 27, 2026. The total program covered 3,790,952 shares, equal to 6.78 percent of share capital, for EUR 250 million.

Including shares already held, the company owned 6,683,050 treasury shares, or 11.95 percent of share capital, after the purchases. The stated purpose is cancellation without reducing share capital, which makes the buyback a capital-allocation event rather than a new operating contract.

H1 revenue stays at EUR 602 million

DiaSorin reported H1 2026 revenue of EUR 602 million, flat year over year at constant exchange rates and down 3.00 percent at current exchange rates, according to Yahoo Finance in the July 31, 2026 earnings call transcript. The difference reflected a EUR 20 million foreign-exchange headwind.

Q2 2026 returned to 4.00 percent revenue growth at constant exchange rates and 3.00 percent at current rates. H1 adjusted EBITDA was EUR 194 million, down 7.00 percent at constant exchange rates, with a 32.00 percent margin.

Management reaffirmed full-year 2026 guidance for 5.00 percent to 6.00 percent revenue growth and a 32.00 percent to 33.00 percent adjusted EBITDA margin. For investors, the key tension is visible in the comparison: operational recovery in Q2 is progressing while the H1 profit base remains below the prior year.

Stock sits 2.61 percent below high

DiaSorin was valued at EUR 3.8 billion on October 7, 2026, while the 52-week range stood at EUR 52.34 to EUR 79.72. The Lang & Schwarz price was therefore 2.61 percent below the 52-week high, calculated from the same euro values.

Trading stays near yearly high

The stock was trading at EUR 77.64 at Lang & Schwarz on October 7, 2026 at 1:10 p.m. CEST, plus 1.34 percent versus the Lang & Schwarz prior close of EUR 76.61 on October 6, 2026. DiaSorin is listed as DIA.MI on Borsa Italiana under ISIN IT0003492391, according to Global Banking and Finance Review. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.